To improve the lives of patients by creating & developing innovative antibody products

Approved Partnered Products
Solid Financial Base
DARZALEX® (daratumumab) / DARZALEX FASPRO™ (daratumumab & hyaluronidase-fihj)³, Kesimptam² (ofatumumab)², TEPEZZA® (teprotumumab)³, Arzerra® (ofatumumab)⁴

Our Own Clinical Pipeline
Potential first-in-class / Best-in-class
Tisotum vedotin⁵, enapotamab vedotin, HexaBody⁶-DR5/DR5, epcoritamab⁶, DuoBody-PD-L1x4-1BB (GEN1046)⁷, DuoBody-CD40x4-1BB (GEN1042)⁷, DuoHexaBody⁶-CD37 (GEN309)⁶ & DuoBody⁶-CD3x5T4 (GEN1044)⁹

Partner-owned Programs in the Clinic
Programs Built on Genmab’s Innovation
15 in clinical development with partners with royalty streams for Genmab should they come to market. Includes 7 DuoBody products with Janssen

Technologies & Preclinical
R&D Engine: Powerhouse of Innovation

Our Three-pronged Strategy
• Focus on core competence
• Turn science into medicine
• Build a profitable & successful biotech

Our Vision
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Proprietary technologies allow us to build a world-class pipeline
Match in-house expertise with strategic partnerships
Strong pipeline of first-in-class / best-in-class products

2020 Guidance

<table>
<thead>
<tr>
<th>Income Statement</th>
<th>DKKM</th>
<th>USDM⁹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>9,250 – 9,850</td>
<td>1,423 – 1,515</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(3,850) – (3,950)</td>
<td>(592) – (608)</td>
</tr>
<tr>
<td>Operating income</td>
<td>5,350 – 5,950</td>
<td>823 – 915</td>
</tr>
</tbody>
</table>

2019 year-end market cap

DKK 96B
~USD 14B¹⁰

2019 year revenue
77% increase vs 2018

DKK 5,366M
~USD 803M¹⁰

2019 year end cash position

DKK 10,971M
~USD 1,643M¹⁰

For more information/contact: genmab.com/ir@genmab.com

¹In dev. by Janssen; ²In dev. by Novartis; ³In dev. by Horizon; ⁴Commercialized by Novartis; ⁵In dev. by AbbVie; ⁶50:50 w/ BioNTech; ⁷Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc. This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov, Nov 4, 2020

Nov 4, 2020

Approved Partnered Products
Solid Financial Base
DARZALEX® (daratumumab) / DARZALEX FASPRO™ (daratumumab & hyaluronidase-fihj)³, Kesimpta² (ofatumumab)², TEPEZZA® (teprotumumab)³, Arzerra® (ofatumumab)⁴

Our Own Clinical Pipeline
Potential first-in-class / Best-in-class
Tisotum vedotin⁵, enapotamab vedotin, HexaBody⁶-DR5/DR5, epcoritamab⁶, DuoBody-PD-L1x4-1BB (GEN1046)⁷, DuoBody-CD40x4-1BB (GEN1042)⁷, DuoHexaBody⁶-CD37 (GEN309)⁶ & DuoBody⁶-CD3x5T4 (GEN1044)⁹

Partner-owned Programs in the Clinic
Programs Built on Genmab’s Innovation
15 in clinical development with partners with royalty streams for Genmab should they come to market. Includes 7 DuoBody products with Janssen

Technologies & Preclinical
R&D Engine: Powerhouse of Innovation

Our Three-pronged Strategy
• Focus on core competence
• Turn science into medicine
• Build a profitable & successful biotech

Our Vision
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Proprietary technologies allow us to build a world-class pipeline
Match in-house expertise with strategic partnerships
Strong pipeline of first-in-class / best-in-class products

2020 Guidance

<table>
<thead>
<tr>
<th>Income Statement</th>
<th>DKKM</th>
<th>USDM⁹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>9,250 – 9,850</td>
<td>1,423 – 1,515</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(3,850) – (3,950)</td>
<td>(592) – (608)</td>
</tr>
<tr>
<td>Operating income</td>
<td>5,350 – 5,950</td>
<td>823 – 915</td>
</tr>
</tbody>
</table>

2019 year-end market cap

DKK 96B
~USD 14B¹⁰

2019 year revenue
77% increase vs 2018

DKK 5,366M
~USD 803M¹⁰

2019 year end cash position

DKK 10,971M
~USD 1,643M¹⁰

For more information/contact: genmab.com/ir@genmab.com

¹In dev. by Janssen; ²In dev. by Novartis; ³In dev. by Horizon; ⁴Commercialized by Novartis; ⁵In dev. by AbbVie; ⁶50:50 w/ BioNTech; ⁷Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc. This document contains forward looking statements that involve significant risks and uncertainties. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov, Nov 4, 2020

Nov 4, 2020
# Innovation Powerhouse

## Genmab Proprietary Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Rights</th>
<th>Indications</th>
<th>Most Advanced Dev. Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tisotumab vedotin</td>
<td>TF</td>
<td>50:50 Genmab</td>
<td>Cervical cancer</td>
<td>Pre-clin.</td>
</tr>
<tr>
<td>Enapotamab vedotin</td>
<td>AXL</td>
<td>Genmab</td>
<td>Solid tumors</td>
<td>I</td>
</tr>
<tr>
<td>Epicoritamab</td>
<td>CD3, CD20</td>
<td>50:50 Genmab</td>
<td>Hem. malig.</td>
<td>II</td>
</tr>
<tr>
<td>DuoBody-PD-L1x4-1BB</td>
<td>PD-L1, 4-1BB</td>
<td>50:50 Genmab</td>
<td>Solid tumors</td>
<td>III</td>
</tr>
<tr>
<td>DuoBody-CD40x4-1BB</td>
<td>CD40, 4-1BB</td>
<td>50:50 Genmab</td>
<td>Solid tumors</td>
<td>Appr.</td>
</tr>
<tr>
<td>HexaBody-DR5/DR5</td>
<td>DR5</td>
<td>Genmab</td>
<td>Solid tumors</td>
<td></td>
</tr>
<tr>
<td>DuoHexaBody-CD37</td>
<td>CD37</td>
<td>50:50 Genmab</td>
<td>AbbVie</td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD3x5T4</td>
<td>5T4</td>
<td>50:50 Genmab</td>
<td>AbbVie</td>
<td></td>
</tr>
</tbody>
</table>

## Products Created by Genmab

| Partner-owned products incorporating Genmab’s Innovation

### Daratumumab
- CD38: Janssen
  - MM
  - AL Amyloidosis
  - Non-MM blood cancers

### Ofatumumab
- CD20: Novartis
  - RMS

### Teprotumumab
- IGF-1R: Horizon
  - TED
dCSc

### Amivantamab
- EGFR, cMet: Janssen
- NSCLC

### Tectistamab
- BCMA, CD3: Janssen
- R/R MM

### Camidanlumab tesirine
- CD25: ADC Therapeutics
- R/R Hodgkin lymphoma
- Solid tumors

### PRV-015 (AMG 714)
- IL-15: Prevention Bio
- Celiac disease

### Mim8
- FIX(a), FX: Novo Nordisk
- Hemophilia A

### Talquetamab
- GPRC5D, CD3: Janssen
- R/R MM

### JNJ-63709178
- CD123, CD3: Janssen
- AML

### JNJ-63890801
- PSMA, CD3: Janssen
- Solid tumors

### JNJ-67571244
- CD33, CD3: Janssen
- R/R AML; MDS

### JNJ-70218902
- Undisclosed: Janssen
- Solid tumors

### HuMax-IL8
- IL8: BMS
- Adv. cancers

### Lu AF824222
- alpha-synuclein: Lundbeck
- Parkinson’s

### ~20 active pre-clinical programs Partnered proprietary programs: HuMab, DuoBody, DuoHexaBody and HexaBody

## Executive Management

- **Founded:** 1999
- **Exchanges:** CSE / Nasdaq
- **Symbol:** GMAB
- **Shares outstanding:** 65,498,346
- **Market Cap as of Nov. 4, 2020:** DKK 154B (~USD 24,064M)

### DARZALEX (daratumumab) / DARZALEX FASPRO (daratumumab & hyaluronidase-fiij)
- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications
- First & only SC CD38 antibody approved
- In development by Janssen
- 2019 net sales by Janssen: $2,998M, DKK 3,132M royalties to Genmab

### TEPEZZA (teprotumumab)
- Dev. & manufactured by Horizon Therapeutics
- Approved in US for thyroid eye disease
- Created under collaboration with Roche
- Genmab to receive mid-single digit royalties on sales

### DuoBody Platform
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

### HexaBody Platform
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

### DuoHexaBody Platform
- Antibody technology that combines DuoBody & HexaBody
- Creates bispecific antibodies with target-mediated enhanced potency

### HexElect Platform
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

---

1. Certain product candidates in development with partners, as noted
2. Genmab developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
3. Out-licensed products marketed by partner
4. See local country prescribing information for precise indications
5. Also approved as Arzerra for certain CLL indications, not in active clinical development
6. Products under development by a third-party incorporating Genmab’s technology and innovation.